Victor C. Gan
Tan Tock Seng Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Victor C. Gan.
Journal of Virology | 2013
Laura Rivino; Emmanuelle A. P. Kumaran; Vojislav Jovanovic; Karen Nadua; En Wei Teo; Shyue Wei Pang; Guo Hui Teo; Victor C. Gan; David C. Lye; Yee Sin Leo; Brendon J. Hanson; Kenneth G. C. Smith; Antonio Bertoletti; David M. Kemeny; Paul A. MacAry
ABSTRACT Dengue virus (DENV) is the principal arthropod-borne viral pathogen afflicting human populations. While repertoires of antibodies to DENV have been linked to protection or enhanced infection, the role of T lymphocytes in these processes remains poorly defined. This study provides a comprehensive overview of CD4+ and CD8+ T cell epitope reactivities against the DENV 2 proteome in adult patients experiencing secondary DENV infection. Dengue virus-specific T cell responses directed against an overlapping 15mer peptide library spanning the DENV 2 proteome were analyzed ex vivo by enzyme-linked immunosorbent spot assay, and recognition of individual peptides was further characterized in specific T cell lines. Thirty novel T cell epitopes were identified, 9 of which are CD4+ and 21 are CD8+ T cell epitopes. We observe that whereas CD8+ T cell epitopes preferentially target nonstructural proteins (NS3 and NS5), CD4+ epitopes are skewed toward recognition of viral components that are also targeted by B lymphocytes (envelope, capsid, and NS1). Consistently, a large proportion of dengue virus-specific CD4+ T cells have phenotypic characteristics of circulating follicular helper T cells (CXCR5 expression and production of interleukin-21 or gamma interferon), suggesting that they are interacting with B cells in vivo. This study shows that during a dengue virus infection, the protein targets of human CD4+ and CD8+ T cells are largely distinct, thus highlighting key differences in the immunodominance of DENV proteins for these two cell types. This has important implications for our understanding of how the two arms of the human adaptive immune system are differentially targeted and employed as part of our response to DENV infection.
BMC Infectious Diseases | 2011
Yee-Sin Leo; Tun Linn Thein; Dale Fisher; Jenny Guek Hong Low; Helen M. L. Oh; Rajmohan L Narayanan; Victor C. Gan; Vernon J. Lee; David C. Lye
BackgroundDengue re-emerges in Singapore despite decades of effective vector control; the infection predominantly afflicts adults. Severe dengue not fulfilling dengue hemorrhagic fever (DHF) criteria according to World Health Organization (WHO) 1997 guideline was increasingly reported. A new WHO 2009 guideline emphasized warning signs and a wider range of severe dengue manifestations. We aim to evaluate the utility of these two guidelines in confirmed adult dengue fatalities.MethodsWe conducted a multi-center retrospective chart review of all confirmed adult dengue deaths in Singapore from 1 January 2004 to 31 December 2008.ResultsOf 28 adult dengue deaths, median age was 59 years. Male gender comprised 67.9% and co-morbidities existed in 75%. From illness onset, patients presented for admission at a median of 4 days and death occurred at a median of 12 days. Intensive care admission was required in 71.4%. Probable dengue was diagnosed in 32.1% by WHO 1997 criteria and 78.6% by WHO 2009. The earliest warning sign was persistent vomiting at a median of 1.5 days. Hematocrit change ≥20% concurrent with platelet count <20 × 10^9/L was associated with the shortest interval to death at a median of 3 days. Only 35.7% of death cases fulfilled DHF criteria by WHO 1997 versus severe dengue in 100.0% by WHO 2009 criteria. Deaths were due to shock and organ failure. Acute renal impairment occurred in 71.4%, impaired consciousness 57.1% and severe hepatitis 53.6%.ConclusionsIn our adult fatal dengue cohort, WHO 2009 criteria had higher sensitivity in diagnosing probable dengue and severe dengue compared with WHO 1997. As warning signs, persistent vomiting occurred early and hematocrit change ≥20% concurrent with platelet count <20 × 10^9/L preceded death most closely.
PLOS Neglected Tropical Diseases | 2011
Luis R. Carrasco; Linda K. Lee; Vernon J. Lee; Eng Eong Ooi; Donald S. Shepard; Tun Linn Thein; Victor C. Gan; Alex R. Cook; David C. Lye; Lee Ching Ng; Yee Sin Leo
Background Dengue illness causes 50–100 million infections worldwide and threatens 2.5 billion people in the tropical and subtropical regions. Little is known about the disease burden and economic impact of dengue in higher resourced countries or the cost-effectiveness of potential dengue vaccines in such settings. Methods and Findings We estimate the direct and indirect costs of dengue from hospitalized and ambulatory cases in Singapore. We consider inter alia the impacts of dengue on the economy using the human-capital and the friction cost methods. Disease burden was estimated using disability-adjusted life years (DALYs) and the cost-effectiveness of a potential vaccine program was evaluated. The average economic impact of dengue illness in Singapore from 2000 to 2009 in constant 2010 US
PLOS Neglected Tropical Diseases | 2012
Linda K. Lee; Victor C. Gan; Vernon J. Lee; A. Tan; Yee Sin Leo; David C. Lye
ranged between
PLOS ONE | 2014
Victor C. Gan; Li-Kiang Tan; David C. Lye; Kwoon-Yong Pok; Shi-Qi Mok; Rachel Chua; Yee-Sin Leo; Lee Ching Ng
0.85 billion and
PLOS Neglected Tropical Diseases | 2013
Tun-Linn Thein; Victor C. Gan; David C. Lye; Chee-Fu Yung; Yee-Sin Leo
1.15 billion, of which control costs constitute 42%–59%. Using empirically derived disability weights, we estimated an annual average disease burden of 9–14 DALYs per 100 000 habitants, making it comparable to diseases such as hepatitis B or syphilis. The proportion of symptomatic dengue cases detected by the national surveillance system was estimated to be low, and to decrease with age. Under population projections by the United Nations, the price per dose threshold for which vaccines stop being more cost-effective than the current vector control program ranged from
American Journal of Tropical Medicine and Hygiene | 2015
Chee-Fu Yung; Kim-Sung Lee; Tun-Linn Thein; Li-Kiang Tan; Victor C. Gan; Joshua G. X. Wong; David C. Lye; Lee Ching Ng; Yee-Sin Leo
50 for mass vaccination requiring 3 doses and only conferring 10 years of immunity to
BMC Infectious Diseases | 2013
Yee Sin Leo; Victor C. Gan; Ee-Ling Ng; Ying-Ying Hao; Lee Ching Ng; Kwoon-Yong Pok; Frederico Dimatatac; Chi Jong Go; David C. Lye
300 for vaccination requiring 2 doses and conferring lifetime immunity. The thresholds for these vaccine programs to not be cost-effective for Singapore were
PLOS Neglected Tropical Diseases | 2014
Emily K. Rowe; Yee-Sin Leo; Joshua G. X. Wong; Tun-Linn Thein; Victor C. Gan; Linda K. Lee; David C. Lye
100 and
PLOS ONE | 2013
Tun-Linn Thein; Yee-Sin Leo; Dale Fisher; Jenny Guek Hong Low; Helen M. L. Oh; Victor C. Gan; Joshua G. X. Wong; David C. Lye
500 per dose respectively. Conclusions Dengue illness presents a serious economic and disease burden in Singapore. Dengue vaccines are expected to be cost-effective if reasonably low prices are adopted and will help to reduce the economic and disease burden of dengue in Singapore substantially.